Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Corcept Therapeutics (CORT) Profit After Tax (2016 - 2025)

Historic Profit After Tax for Corcept Therapeutics (CORT) over the last 13 years, with Q3 2025 value amounting to $19.7 million.

  • Corcept Therapeutics' Profit After Tax fell 5834.2% to $19.7 million in Q3 2025 from the same period last year, while for Sep 2025 it was $106.1 million, marking a year-over-year decrease of 2517.88%. This contributed to the annual value of $141.2 million for FY2024, which is 3304.03% up from last year.
  • Corcept Therapeutics' Profit After Tax amounted to $19.7 million in Q3 2025, which was down 5834.2% from $35.1 million recorded in Q2 2025.
  • Corcept Therapeutics' Profit After Tax's 5-year high stood at $47.2 million during Q3 2024, with a 5-year trough of $15.9 million in Q1 2023.
  • In the last 5 years, Corcept Therapeutics' Profit After Tax had a median value of $27.8 million in 2024 and averaged $28.2 million.
  • As far as peak fluctuations go, Corcept Therapeutics' Profit After Tax skyrocketed by 8887.42% in 2023, and later crashed by 5834.2% in 2025.
  • Corcept Therapeutics' Profit After Tax (Quarter) stood at $32.1 million in 2021, then tumbled by 48.21% to $16.6 million in 2022, then surged by 88.87% to $31.4 million in 2023, then fell by 1.94% to $30.7 million in 2024, then tumbled by 36.03% to $19.7 million in 2025.
  • Its Profit After Tax was $19.7 million in Q3 2025, compared to $35.1 million in Q2 2025 and $20.5 million in Q1 2025.